UCSF home page About UCSF UCSF Medical Center
UCSF home page | About UCSF | UCSF Medical Center

Skip to TransPortal content

Decrease the text sizeRestore original text sizeIncrease the text size Enlarge Text
Click to increase the text size.
Restore Text
Click to restore original text size.
Reduce Text
Click to decrease the text size.
Transporter Database banner  
Decrease the text size | Restore text size | Increase the text size
Text Sizer image
Home About and More Information Transporter Data Index
Search:  
 

SLC22A12

Synonyms: OAT4L, RST, URAT1

Entrez Gene Link

Expression Data
Substrate Information
Inhibitor Information
Clinical Drug-drug Interactions

Expression Data

Expression data for other tissues could be found in http://pharmacogenetics.ucsf.edu/gtex/index.html

Asterisk indicates important transporters in the organ as identified in the organ diagram.

Organ Source Relative Expression
Brain Nishimura BLQ
Kidney* Nishimura    0.976
Liver Nishimura BLQ
Placenta Nishimura BLQ
Small Intestine Nishimura BLQ
Kidney* Mean across all PMT Samples 25.102
Liver Mean across all PMT Samples    0.336
Note that relative expression values should only be compared between entries of the same source.

Back to top

In Vitro Substrates

Substrate Km (μM) Cell System Reference
Ammonium perfluorooctanoate 64.1 HEK293 cells Yang, 2010
Oxypurinol 794 URAT1-expressing oocytes Iwanaga, 2005
Uric acid 357.6 URAT1-expressing oocytes Iwanaga, 2007

ND = not determined
1 denotes drugs that can potentially be used as in vitro substrates for studies of the transporter as defined by the FDA as of March 2022
2 denotes drugs that can potentially be used as in vitro inhibitors for studies of the transporter as defined by the FDA as of March 2022
3 denotes drugs that can potentially be used as clinical substrates for studies of the transporter as defined by the FDA as of March 2022
4 denotes drugs that can potentially be used as clinical inhibitors for studies of the transporter as defined by the FDA as of March 2022


Back to top

In Vitro Inhibitors

Inhibitor IC50 (μM) Ki (μM) Substrate used Cell System Reference
Benzbromarone ~0.3 Uric acid HEK293-URAT1 Yu, 2007
Benzbromarone 0.13 Uric acid HEK293-URAT1 Uetake, 2010
Fenofibric acid 35.68 Uric acid HEK293-URAT1 Uetake, 2010
Losartan 0.0077 Uric acid URAT1-expressing oocytes Iwanaga, 2007
Losartan 570.5 Uric acid HEK293-URAT1 Uetake, 2010
Morin ~2 Uric acid HEK293-URAT1 Yu, 2007
Morin 5.74 Uric acid HEK293-URAT1 Yu, 2007
Pratosartan 0.0067 Uric acid URAT1-expressing oocytes Iwanaga, 2007
Probenecid ~50 Uric acid HEK293-URAT1 Yu, 2007
Sulfinpyrazone ~100 Uric acid HEK293-URAT1 Yu, 2007
Telmisartan 0.0182 Uric acid URAT1-expressing oocytes Iwanaga, 2007
Uric acid 170 Oxypurinol URAT1-expressing oocytes Iwanaga, 2005

ND = not determined
1 denotes drugs that can potentially be used as in vitro substrates for studies of the transporter as defined by the FDA as of March 2022
2 denotes drugs that can potentially be used as in vitro inhibitors for studies of the transporter as defined by the FDA as of March 2022
3 denotes drugs that can potentially be used as clinical substrates for studies of the transporter as defined by the FDA as of March 2022
4 denotes drugs that can potentially be used as clinical inhibitors for studies of the transporter as defined by the FDA as of March 2022


Back to top

Clinical Drug-Drug Interactions

No drug-drug interaction information.


Back to top

Contact us | Glossary

Blue banner